Enliven Therapeutics ELVN
$46.53 +$0.12 (+0.26%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $46.53 0.00%
Open$46.05
Prev close$46.41
Day range$45.64 – $47.83
Volume933.6K
Market cap$3.42B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$36.05M-43.6% YoY
Net profit-$27.70M-37.5% YoY
Diluted EPS-$0.36-12.5% YoY
Free cash flow-$12.65M+4.7% YoY
Operating cash flow-$12.56M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-16.8%
Return on assets-16.4%
Return on invested capital-20.0%
Current ratio45.95
Liabilities / assets2.3%
Cash & investments$884.35M
Total debt$805,000.00
Net cash (debt)$883.55M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $36.05M | $37.21M | $27.82M | $119.66M | $34.29M |
| Selling and Admin Expenses | $8.02M | $8.21M | $7.14M | $33.80M | $13.04M |
| -General & Admin Expense | $8.02M | $8.21M | $7.14M | $33.80M | $13.04M |
| Research & Development | $28.02M | $29.00M | $20.69M | $85.86M | $21.25M |
| Operating Profit | -$36.05M | -$37.21M | -$27.82M | -$119.66M | -$34.29M |
| Net Non-Operating Interest Income (Expense) | $8.35M | $4.73M | $4.20M | $16.01M | $4.62M |
| Non-Operating Interest Income | $8.35M | $4.73M | $4.20M | $16.01M | $4.62M |
| Other Income (Expense) | -$11,000.00 | -$8,000.00 | – | -$49,000.00 | $0.00 |
| Other Non-Operating Income (Expenses) | -$11,000.00 | -$8,000.00 | – | -$49,000.00 | $0.00 |
| Pretax Profit | -$27.70M | -$32.49M | -$23.63M | -$103.69M | -$29.67M |
| Net Profit | -$27.70M | -$32.49M | -$23.63M | -$103.69M | -$29.67M |
| Profit from Continuing Operations | -$27.70M | -$32.49M | -$23.63M | -$103.69M | -$29.67M |
| Net Income to Parent Company | -$27.70M | -$32.49M | -$23.63M | -$103.69M | -$29.67M |
| Net Income to Common Stockholders | -$27.70M | -$32.49M | -$23.63M | -$103.69M | -$29.67M |
| Basic EPS | -$0.36 | -$0.49 | -$0.38 | -$1.83 | -$0.48 |
| Diluted EPS | -$0.36 | -$0.49 | -$0.38 | -$1.83 | -$0.48 |
| Special Income (Charges) | – | – | – | $0.00 | $0.00 |
| -Less:Restructuring and Mergern & Acquisition | – | – | – | $0.00 | $0.00 |
| Tax | – | – | – | $0.00 | $0.00 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $897.23M | $910.22M | $464.85M | $476.17M | $476.17M |
| Total Current Assets | $894.76M | $907.34M | $463.14M | $474.88M | $474.88M |
| Cash and Cash Equivalents & Short-Term Investments | $884.35M | $895.16M | $452.40M | $462.62M | $462.62M |
| -Cash and Cash Equivalents | $151.67M | $135.51M | $132.18M | $98.90M | $98.90M |
| -Short Term Investments | $732.68M | $759.65M | $320.22M | $363.73M | $363.73M |
| Other Current Assets | $10.41M | $12.18M | $10.74M | $12.26M | $12.26M |
| Total Non-Current Assets | $2.47M | $2.88M | $1.72M | $1.29M | $1.29M |
| Net PPE | $1.51M | $1.64M | $310,000.00 | $417,000.00 | $417,000.00 |
| -Gross PPE | $1.77M | $1.89M | $553,000.00 | $646,000.00 | $646,000.00 |
| -Accumulated Depreciation | -$263,000.00 | -$250,000.00 | -$243,000.00 | -$229,000.00 | -$229,000.00 |
| Non-Current Deferred Assets | $0.00 | $0.00 | $217,000.00 | $217,000.00 | $217,000.00 |
| Other Non-Current Assets | $962,000.00 | $1.24M | $1.19M | $656,000.00 | $656,000.00 |
| Total Liabilities | $20.28M | $15.07M | $11.49M | $16.57M | $16.57M |
| Total Current Liabilities | $19.47M | $14.16M | $11.49M | $16.57M | $16.57M |
| Payables | $2.73M | $371,000.00 | $1.64M | $2.16M | $2.16M |
| -Accounts Payable | $2.73M | $371,000.00 | $1.64M | $2.16M | $2.16M |
| Current Accrued Expenses | $10.75M | $10.03M | $7.18M | $9.36M | $9.36M |
| Short-Term Debt and Capital Lease Obligation | $510,000.00 | $597,000.00 | $302,000.00 | $399,000.00 | $399,000.00 |
| -Current Capital Lease Obligation | $510,000.00 | $597,000.00 | $302,000.00 | $399,000.00 | $399,000.00 |
| Other Current Liabilities | $174,000.00 | $133,000.00 | $107,000.00 | $351,000.00 | $351,000.00 |
| Total Non-Current Liabilities | $805,000.00 | $913,000.00 | $0.00 | $0.00 | $0.00 |
| Long Term Debt and Capital Lease Obligation | $805,000.00 | – | – | – | – |
| -Long Term Capital Lease Obligation | $805,000.00 | – | – | – | – |
| Total Equity | $876.95M | $895.15M | $453.37M | $459.60M | $459.60M |
| Stockholders' Equity | $876.95M | $895.15M | $453.37M | $459.60M | $459.60M |
| Capital Stock | $74,000.00 | $73,000.00 | $61,000.00 | $59,000.00 | $59,000.00 |
| -Common Stock | $74,000.00 | $73,000.00 | $61,000.00 | $59,000.00 | $59,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $1.31B | $1.30B | $824.48M | $806.37M | $806.37M |
| Retained Earnings | -$430.98M | -$403.28M | -$370.79M | -$347.17M | -$347.17M |
| Gains/Losses Not Affecting Retained Earnings | -$3.51M | -$1.91M | -$382,000.00 | $334,000.00 | $334,000.00 |
| Other Non-Current Liabilities | – | $913,000.00 | – | – | – |
| Restricted Cash | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$12.56M | -$18.53M | -$19.29M | -$70.30M | -$15.84M |
| Net cash flow from continuing operations | -$12.56M | -$18.53M | -$19.29M | -$70.30M | -$15.84M |
| Net Income from Continuing Operations | -$27.70M | -$32.49M | -$23.63M | -$103.69M | -$29.67M |
| Depreciation & Depletion & Amortization | $13,000.00 | $7,000.00 | $14,000.00 | $263,000.00 | $46,000.00 |
| Other Non-Cash Items | $196,000.00 | $126,000.00 | $93,000.00 | $353,000.00 | $92,000.00 |
| Change in Working Capital | $7.95M | -$605,000.00 | -$3.43M | -$1.12M | $1.22M |
| -Change in Prepaid Assets | $2.06M | -$2.16M | $1.65M | -$1.11M | -$694,000.00 |
| -Change in Payables and Accrued Expense | $6.09M | $1.68M | -$4.98M | $321,000.00 | $2.00M |
| -Change in Other Current Liabilities | -$196,000.00 | -$129,000.00 | -$97,000.00 | -$337,000.00 | -$91,000.00 |
| Net cash flow from investing | $26.33M | -$441.57M | $42.53M | -$173.84M | $12.38M |
| Net Cash Flow from Continuing Investing Activities | $26.33M | -$441.57M | $42.53M | -$173.84M | $12.38M |
| Net PPE Purchase and Sale | -$94,000.00 | -$99,000.00 | $0.00 | $55,000.00 | $213,000.00 |
| Net Investment Purchase and Sale | $26.42M | -$441.47M | $42.53M | -$173.90M | $12.17M |
| Financing Cash Flow | $2.39M | $463.42M | $10.05M | $218.87M | $623,000.00 |
| Net Cash Flow from Continuing Financing Activities | $2.39M | $463.42M | $10.05M | $218.87M | $623,000.00 |
| Net Common Stock Issuance | -$666,000.00 | – | – | $216.17M | $0.00 |
| Proceeds from Stock Option Exercised | $3.05M | $29.94M | $10.05M | $2.92M | $721,000.00 |
| Ending Cash Balance | $151.67M | $135.51M | $132.18M | $98.90M | $98.90M |
| Net Change in Cash | $16.16M | $3.32M | $33.29M | -$25.28M | -$2.84M |
| Beginning Cash Balance | $135.51M | $132.18M | $98.90M | $124.17M | $101.73M |
| Free Cash Flow | -$12.65M | -$18.63M | -$19.29M | -$70.46M | -$15.84M |
| Gain/Loss from Continuing Operations | – | – | – | $106,000.00 | – |
| Net Other Financing Charges | – | – | – | -$217,000.00 | -$98,000.00 |
No comments yet — be the first to weigh in on ELVN.
Sign in to join the discussion.